



ÉCOLE PRATIQUE
des HAUTES ÉTUDES



Antibiotics and others pharmaceuticals in the environment



Introduction

- Human activities generate numerous environmental disturbances:
 - Biological
 - Physical: Heat, Suspended solids (SS), Radioactivity
 - Chemical: Metals, Organic molecules (nutrients, micropollutants)
- Contaminant $\neq$ pollutant
 - Chapman, Env. Int., 2007
 - « Contamination is simply the presence of a substance where it should not be or at concentrations above background. Pollution is contamination that results in or can result in adverse biological effects to resident communities. All pollutants are contaminants, but not all contaminants are pollutants. »




Micropollutants

- Lists of hazardous substances (1976) or WFD priority substances (2000) → Families of molecules
 - Different behaviours within the same family
 - Indicators of sources and dispersion modes
 - Regulatory developments Substitute molecules
- Pesticides : DDT, triazines, organophosphates
- Persistent organic pollutants (POP) : PCBs, HCB...
- Accidental synthesis products : Dioxins, PAHs...
- Plasticizers : phthalates, BPA...
- Flame retardants: PBDEs, TBBPA...
- Surfactants : alkylphenols
- « Undesirable molecules »
 - Drugs: antibiotics (sulphonamides, tetracyclines, fluoroquinolones, etc) and others pharmaceuticals
 - Estrogens (hormones) : 17α et 17β estradiol
 - Preservatives (parabens, triclosan, etc...)
 - Synthetic musk (galaxolide, tonalide, etc)



Pathways of diffusion of micropollutants in the environment



(Pechan and de Vries, 2013)

What about Antibiotics ?
And their adverse effects ?



Outline :


- History of Antibiotics (ATB)
- Uses of ATB
- Development of Antimicrobial resistance (AMR)
- Rôle of environmental Pressure
- How ATB enter in environment
- Levels of ATB concentrations in environment
- Implications for wildlife
- Others pharmaceuticals



History of antibiotics

- History

- Penicillin (Fleming 1928/Chain & Florey 1939/ treat. 1941)
- Sulfonamide (Dogmak 1931 / Trefouel 1935)
- 1940 actinomycin; 1944 streptomycin
- 1946: industrialisation and marketing



- Origins

Most current antibiotics are either natural molecules produced by bacteria (mostly actinomycetes) and fungi, that can be modified chemically, or fully synthetic (sulfonamide and trimethoprim)

ANTIBIOTIC INTRODUCED

1943 Penicillin

1950 Tetracycline

1953 Erythromycin

1960 Methicillin

1967 Gentamicin

1972 Vancomycin

1985 Imipenem and ceftazidime

1996 Levofloxacin

2000 Linezolid


2003 Daptomycin

2010 Ceftaroline



A major tool of modern medicine

- The miracle of antibiotics
 - Save life of soldiers (WW2)
 - ↗ % survival during bacterial infection
 - saved millions of lives
 - Between 1944 and 1972 human life expectancy jumped by eight years
- Uses
 - Bacteria
 - Surgery
 - Oncology
 - transplantation



Austrian R and Gold J, Ann of Intern Med 1964



A major tool for veterinary medicine

- mostly deals with groups of animals (livestock)
- treat dogs, cats, horses individually

- Uses


- as growth promoters

- 49% OIE/WOAH members countries

- In Europe, Use banned in 2006

- therapeutic use (with a marketing authorization or not)

Proportion of OIE Member Countries banning the use of antimicrobial agents as growth promoters




152 questionnaires received from 178 OIE Member Countries = **85% replied.**



Development of Antimicrobial resistance

- Natural processus since -3,8 billion years (Bacteria) as defensive mechanism
- Increase uses (humans, animals) favours the development of Antimicrobial resistance (AMR)




ANTIBIOTIC RESISTANCE IDENTIFIED		ANTIBIOTIC INTRODUCED	
Penicillin-R <i>Staphylococcus</i>	1940	1943	Penicillin
		1950	Tetracycline
		1953	Erythromycin
Tetracycline-R <i>Shigella</i>	1959	1960	Methicillin
Methicillin-R <i>Staphylococcus</i>	1962		
Penicillin-R pneumococcus	1965	1967	Gentamicin
Erythromycin-R <i>Streptococcus</i>	1968	1972	Vancomycin
Gentamicin-R <i>Enterococcus</i>	1979		
Ceftazidime-R Enterobacteriaceae	1987	1985	Imipenem and ceftazidime
Vancomycin-R <i>Enterococcus</i>	1988		
Levofloxacin-R pneumococcus	1996	1996	Levofloxacin
Imipenem-R Enterobacteriaceae	1998		
XDR tuberculosis	2000	2000	Linezolid
Linezolid-R <i>Staphylococcus</i>	2001		
Vancomycin-R <i>Staphylococcus</i>	2002	2003	Daptomycin
PDR- <i>Acinetobacter</i> and <i>Pseudomonas</i>	2004/5		
Ceftriaxone-R <i>Neisseria gonorrhoeae</i>	2009	2010	Ceftaroline
PDR-Enterobacteriaceae			
Ceftaroline-R <i>Staphylococcus</i>	2011		

Ventola, 2015



Development of Antimicrobial resistance

- Natural processus since -3,8 billion years (Bacteria) as defensive mechanism
- Increase uses (humans, animals) favours the development of Antimicrobial resistance (AMR)




Ventola, 2015

ANTIBIOTIC RESISTANCE IDENTIFIED		ANTIBIOTIC INTRODUCED	
Penicillin-R <i>Staphylococcus</i>	1940	1943	Penicillin
		1950	Tetracycline
		1953	Erythromycin
Tetracycline-R <i>Shigella</i>	1959	1960	Methicillin
Methicillin-R <i>Staphylococcus</i>	1962		
Penicillin-R pneumococcus	1965	1967	Gentamicin
Erythromycin-R <i>Streptococcus</i>	1968	1972	Vancomycin
Gentamicin-R <i>Enterococcus</i>	1979		
Ceftazidime-R Enterobacteriaceae	1987	1985	Imipenem and ceftazidime
Vancomycin-R <i>Enterococcus</i>	1988		
Levofloxacin-R pneumococcus	1996	1996	Levofloxacin
Imipenem-R Enterobacteriaceae	1998		
XDR tuberculosis	2000	2000	Linezolid
Linezolid-R <i>Staphylococcus</i>	2001		
Vancomycin-R <i>Staphylococcus</i>	2002	2003	Daptomycin
PDR- <i>Acinetobacter</i> and <i>Pseudomonas</i>	2004/5		
Ceftriaxone-R <i>Neisseria gonorrhoeae</i>	2009	2010	Ceftaroline
PDR-Enterobacteriaceae			
Ceftaroline-R <i>Staphylococcus</i>	2011		



Development of Antimicrobial resistance

Antibiotic Resistance of *Escherichia coli*




Center for Disease Dynamics, Economics & Policy (cddep.org)

- What do you observe ?



Development of Antimicrobial resistance

Antibiotic Resistance of *Escherichia coli*




Center for Disease Dynamics, Economics & Policy (cddep.org)

- What do you observe ?

- Case of India

Antibiotic Resistance of *Escherichia coli* in India



Center for Disease Dynamics, Economics & Policy (cddep.org)

<https://resistancemap.cddep.org/About.php>




Development of Antimicrobial resistance

- Causes :
 - Overuse
 - Misuses
 - Use as growth promoter
 - Reduction in the number of discoveries



therapeutic deadlock ?



FDA Center for Drug Evaluation and Research




Development of Antimicrobial resistance


Great concern since 2000s

In June 2021, at the G7,
antimicrobial resistance
was described as
a **"silent pandemic"**

Consequences of bacterial resistance on morbidity and mortality



Development of Antimicrobial resistance



- One of the 10 greatest threats to public health (WHO)
- Significant cost: €290 million in France (2016)
- Notion of co-morbidity
- Therapeutic impasse

Deaths attributable to antimicrobial resistance every year by 2050 - Review on Antimicrobial Resistance 2014




Development of Antimicrobial resistance

Great concern since 2000s

In June 2021, at the G7, antimicrobial resistance was described as a **"silent pandemic"**

Potential consequences for the future (2015-2050)





Source: The review on AMR, Jim O'Neill 2014





Evolution of consumption of ATB in humans

Antibiotics, human consumption 2005-2014, OECD



Brown et al. 2021




... In animals

- Reduce the use as growth promoters
- In 2017, In China, an emergence of Colistin resistance in humans and animals
 - More than 8 000 tons of colistin stopped in animal feed in China (April 30, 2017)
 - Still approved for treating sick animals

- Reduce the authorized uses


Animal weight (tons) treated with antibiotics (France)



National Agency for Veterinary Medicinal Products (France) 2017 Report



AMR in humans and animals are interconnected




- AMR in humans and animals are interconnected, that means antibiotic use both in humans and animals selects for resistance.
- In particular, antibiotic use in animals selects for resistance in animal commensals and animal pathogens.
- And later on, resistant bacteria or resistance genes can be transmitted to bacteria either from the same bacterial species or other bacterial species such as human commensals or human pathogens.
- Antibiotic use in animals can also select for resistance in zoonotic bacteria that can then be transmitted to humans and cause treatment failures.

Dewulf et al. 2020



What is the role of Environment in AMR ?



The flow of antimicrobial resistance and antibiotics across the One Health continuum of food-producing animals, humans, and the environment. Grey arrows indicate flow of resistance genes and resistant bacteria; blue arrows indicate flow of antibiotic residues.


- Under antibiotic pressure
- AMR development
- ATB and AMR release in environment

In environment, are concentrations levels of ATB and bacteria sufficient to participate to the AMR ?

How ATB enter the environment ?




Main sources and contamination routes of soil and water by antibiotic-resistant bacteria and antibiotic residues







Sources and pathways in the environment






Sources and pathways in the environment






Sources and pathways in the environment





Sources and pathways in the environment



Quantities consumed per year in France


Antibiotique	Tonnes/an
Pénicillines	500
Streptogramines	50
Céphalosporines (C3G et C4G)	35
Fluoroquinolones	25

Antibiotique	Tonnes/an
Tétracycline	180
Sulfamides	90
Pénicillines	71
Aminosides	53

Ansm 2020 ; pour la médecine vétérinaire : Anses/ANMV 2020



Sources and pathways in the environment



Quantities consumed per year in France

Antibiotique	Tonnes/an
Pénicillines	500
Streptogramines	50
Céphalosporines (C3G et C4G)	35
Fluoroquinolones	25

Antibiotique	Tonnes/an
Tétracycline	180
Sulfamides	90
Pénicillines	71
Aminosides	53

⇒ Excreted as unchanged or metabolized form

Ansm 2020 ;
Anses/ANMV 2020




Human excretion rates

		Taux d'excrétion %	
		Inchangé	Métabolisé
<i>Macrolides</i>	Tylosine	28 - 76 ^a	
	Erythromycine	> 60 ^b	
<i>Tétracyclines</i>	Chlorophénicole	5 - 10 ^a	
	Tétracycline	80 - 90 ^a	
	Chlorotétracycline	< 70 ^a	
	Oxytétracycline	< 80 ^a	
<i>β-lactamines</i>	Amoxiciline	80 - 90 ^a	10 - 20 ^a
	Ampiciline	30 - 60 ^a	20 - 30 ^a
	Penicilline G	50 - 70 ^a	30 - 70 ^a
<i>Sulfodinamides</i>	Sulfaméthoxazole	15 ^a	
	Sulphaméthoxine	~ 15 ^a	
<i>Diaminopyrimidines</i>	Triméthoprime	50 ^b	
<i>Quinolones et Fluoroquinolone</i>	Acide nalidixique	20 ^b	
	Fluméquine	10 ^b	
	Norfloxacine	70 ^b	
	Ofloxacine	80 ^b	
	Ciprofloxacine	75 - 85 ^b	
<i>Imidazoles</i>	Ornidazole	5 ^b	
<i>Glycopeptides</i>	Vancomycine	90 ^b	
<i>Aminoglycosides</i>	Streptomycine	< 66 ^a	



Human medicine




- [ATB] in hospital effluent > Domestic effluent
- Vancomycine only found in hospital effluent

Dinh et al, 2017




Veterinary medicine



[ATB] in manure in Blaise Catchment, France (Tamtam, 2008)




Sources and pathways in the environment






Waste water treatment plant



1. **Primary treatment:** separating suspended solids (SS) from wastewater by flocculation / coagulation / settling and flotation processes –
2. **Secondary treatment:** advanced biological treatment methods, leveraging the ability of certain bacteria, to eliminate dissolved pollutants contained in wastewater – such as carbon, nitrogen and phosphorus pollutants.
3. **Tertiary treatment and reuse:** this final stage looks to remove any remaining dissolved solids from purified water and disinfected wastewater so that the treated water can be reused for other purposes (chlorination, ozonation, UV treatment)
4. **Quaternary treatment** : elimination of organic micropollutants by adsorption on activated carbon or ozonation
5. **Sludge treatment:** the pollutants eliminated during treatment operations become sludge, and recycling



Removal of ATB (and bacteria) by WWTP




Source : Wang et al., 2020



Removal of ATB (and bacteria) by WWTP



- In France,
- ATB (and bacteria) removal depend on technology used !
 - Membranes
 - Biofiltrations
 - Nanofiltrations
- Impact of ATB on WWTP efficiency (biological treatment)





Hospital vs domestic WWTP

Hospital WWTP
1 700 inhab
+ Hospital (240
beds)




Dinh et al, 2017




Sludge and soil contaminations

ATB content in sludge (Hospital WWTP)



- Fluoroquinolones : few mg/Kg
- Others molecules : < 0,5 mg/Kg

ATB contents in soil after sludge spreading




3 fluoroquinolones : < 0,05 mg/Kg



Fate of ATB contents in soils

- Case of fluoroquinolones




- Source : only sludge
 - No ATB in depth
 - No impact of tillage
- ⇒ Degradation of compounds

Importance of Physico-chemical properties of molecules (persistence, Half-life, solubility, adsorption...)

Reminder : Origin of ATB : Bacteria and fungi in soils !!!



Sources and pathways in the environment



Tamtam, 2008)



Fish farm



**Permanent treatment
(antibiotics in feed)
-> preventive treatment**

**Occasional treatment of
a pond**




Environmental Impact of Acide oxolic and Flumequine used in fish farm

Direct introduction of ATB in water

- from undigested feed (dissolved form)
- fractions excreted by fish (form associated with solid material: feed, faeces)


Cravedi et al [1987], 90% of the administered treatment is not metabolised by the fish.

During an occasional Treatment by Flumequine



Concentrations of Flumequine in river

No treatment period





Concentrations of Ac Oxolinic in sediment river

No ATB in water, only Ac Oxolinic in sediment



Surface water contamination

- By pharmaceutical industries
- By WWTP (hospital)





Water and Sediment contamination

Impact of WWTP effluent

Upstream : low

Downstream :

{ water : ~ 4 µg/L
Sediments: ~ 2 mg/Kg


decrease in distance from the discharge

In Water: fluoroquinolones et sulfonamide (downtown)

Far Downstream: sulfonamides mainly

Sediments : ~ 90% fluoroquinolones


Dissipation of fluoroquinolones in water ~ adsorbed in sediment





Impact on the ecosystem


- Bioaccumulation of ATB in Invertebrate species (Gammarus Pulex)



- 6 molecules detected including 5 fluoroquinolones
- Contents: Juveniles > Adults (more efficient elimination in adults?)
- Sulfamides, glycopeptides, macrolides : detected in water, not in Gammarus



- Bioaccumulation in wild fish (stone loach)




- ❖ 5 antibiotiques detected including 4 fluoroquinolones
- ❖ concentration in the same order than water contamination



Summary : ATB concentrations and AMR

- Concentrations vs minimal inhibitory concentrations MICs
=> promote AMR





Larsson and Flach, 2022



Summary : ATB concentrations and AMR


In the Seine river



Passerat et al., 2010



Summary : Hotspot



- Hotspot : 3 conditions
- Importance of studies about environmental fate of molecules
- Hotspot :
 - In regions with open defecation
 - In regions with pharma manufacturings sites (Asia)



Others pharmaceuticals and their impacts



Environmental consequences of the use of an anti-inflammatory drug on livestock

Diclofenac: anti-inflammatory drug

livestock: treatment of any inflammation, fever and/or pain associated with disease or injury.

In India, Vultures feed on the carcasses of these livestock
➡ mortality: kidney disease.




The toxicity of this anti-inflammatory drug has been found in other raptors, in storks, cranes and owls

Oaks et al. (2004)




Impacts of veterinary products on coprophagous insects: consequences on the degradation of excreta in pastures



Clichés : G. Virrouvet



Impacts of veterinary products on coprophagous insects: consequences on the degradation of excreta in pastures



Antiparasitic treatments: Ivermectin

Impact :

disappearance of recycling organisms

Accumulation of dung : fly outbreak and loss of grazing area




Clichés : G. Virrouvet



Others pharmaceuticals in aquatic environment

A 1st Study

Kolpin et al, 2002




139 streams

95 organic pollutants including 22 drugs + 31 human and / or veterinary antibiotics + 18 hormones and steroids



Place of drug among pollutants




Kolpin et al. 2002




Drug : worldwide consumption

Exhibit 6: Medicine Spending in 2020 US\$ by Geography, Product Type and Disease Area





Drug : worldwide consumption



Global Use of Medicines in 2020. Report by the IMS Institute for Healthcare Informatics



Cumulative Concentration (ng/L)

90th Percentile **80th Percentile** **70th Percentile**

Location	Cumulative Concentration (ng/L)
Pakistan_Lahore	7000
Bolivia_LaPaz	6800
Ethiopia_AddisAbaba	5200
India_Delhi	4700
Tunisia_Tunis	4400
Congo_DRC_Bukavu	3800
Armenia_Yerevan	3400
Kenya_Nairobi	2800
Costa Rica_San Jose	2500
Nigeria_Lagos	2200
Uruguay_Montevideo	2000
Algeria_West Bank	1900
Congo_DRC_Kinshasa	1800
Spain_Madrid	1700
Argentina_Buenos Aires	1600
China_Panyu	1400
Antigua_St John's	1800
Malaysia_Kajang	1400
Israel_Alexander river	1400
Ghana_Accra	1200
Bulgaria_Sofia	1200
India_Hyderabad	1200
Luxembourg_City	1000
Belgium_Brussels	1000
USA_Dallas	1000
Scotland_Glasgow	1000
Iraq_Baghdad	1400
Angola_Luanda	1300
Hong_Kong_Kai Tak River	800
Costa Rica_Brazzaville	800
Georgia_Tbilisi	1000
Bangladesh_Dhaka	1000
Philippines_Marila	600
Turkey_Saray	600
South Africa_Pretoria	500
Indonesia_Citaram	500
USA_Las Vegas	500
Ireland_Belfast	500
Germany_Tubingen	500
Austria_Vienna	500
Ecuador_Guayaquil	800
Malawi_Bamako	700
South Korea_Seoul	700
Sri Lanka_Colombo	700

The chart displays the cumulative concentration of a substance in ng/L for 30 different locations. The y-axis ranges from 0 to 4000 ng/L. The locations are grouped into three categories based on percentile thresholds: 60th Percentile (top), 50th Percentile (middle), and 40th Percentile (bottom). Each bar is color-coded and includes an error bar. Significance markers (+) are present for locations that exceed the 60th percentile threshold.

Location	Cumulative Concentration (ng/L)	Percentile Category	Significance
USA_Denver	~3950	60th Percentile	
Chile_Santiago	~3900	60th Percentile	
Tanzania_Dar es Salaam	~3850	60th Percentile	+
Panama_Panama City	~3750	60th Percentile	+
UK_London	~3650	60th Percentile	
USA_North Liberty	~3300	60th Percentile	
Peru_Huancayo	~3400	60th Percentile	+
Colombia_Cali	~3050	60th Percentile	
Lesotho_Maseru	~3000	60th Percentile	+
Netherlands_Utrecht	~2950	60th Percentile	
Romania_Bucharest	~2850	60th Percentile	+
Serbia_Belgrade	~2800	60th Percentile	
China_Guangzhou	~2750	60th Percentile	
Portugal_Lisbon	~2650	60th Percentile	
UK_Leeds	~2600	60th Percentile	
USA_New York City	~2450	60th Percentile	
Canada_Toronto	~2350	60th Percentile	
Cameroon_Yaounde	~2500	60th Percentile	+
Mexico_Puerto Vallarta	~2150	60th Percentile	
Brazil_Natal	~2100	60th Percentile	
Hungary_Budapest	~1800	60th Percentile	
Belgium_Antwerp	~1750	60th Percentile	
Denmark_Odense	~1700	60th Percentile	
Czech Republic_Prague	~1500	60th Percentile	
Thailand_Bangkok	~1450	60th Percentile	
Hong Kong_Lam T'suen	~1400	60th Percentile	
Taiwan_Taoyuan	~1400	60th Percentile	
Germany_Berlin	~1350	60th Percentile	
UK_York	~1350	60th Percentile	
Brazil_America	~1300	60th Percentile	
China_Faso_Ouagadougou	~1450	60th Percentile	+
Germany_Frankfurt	~1200	60th Percentile	
Japan_Magome	~1150	60th Percentile	
Russia_Moscow	~1100	60th Percentile	
Switzerland_Basel	~1050	60th Percentile	
King George Island	~1150	60th Percentile	+
Croatia_Zagreb	~950	60th Percentile	
USA_Hawaii_Kauai	~850	60th Percentile	
Canada_Calgary	~1050	60th Percentile	+
South Sudan_Juba	~800	60th Percentile	
Slovakia_Bratislava	~750	60th Percentile	
France_Paris	~700	60th Percentile	
France_Beaujeu	~650	60th Percentile	
Greece_Oinofya	~600	60th Percentile	
Brunei_Brunel River	~850	60th Percentile	+
Kazakhstan_Astana	~550	60th Percentile	+


- Continued...





Pharmaceutical pollution in the world's rivers

Wilkinson et al. 2022




- 53/61 APIs detected once
- 15 compounds > 20% detection
- > 40% Carbamazepine, Metformine, Caffeine
- Trimethoprim and sulfamethoxazole 1st ATB (40%)




Pharmaceutical pollution in the world's rivers

Wilkinson et al. 2022




- highest concentrations :
 - paracetamol,
 - caffeine,
 - metformin,
 - fexofenadine,
 - sulfamethoxazole (antimicrobial),
 - metronidazole (antimicrobial),
 - and gabapentin





Example of removal in WWTP




As ATB, removals in WWTP of pharmaceutical are not 100%



Study on emerging contaminants in French waters

- ONEMA & INERIS, 2014
- Three campaigns: spring, summer, fall
- 158 locations in France
- 22 pharmaceuticals from 10 therapeutic families
- 75% pharmaceuticals quantified at least once in water and 52% in sediments

Catégorie	Paramètre	FQ C1	FQ C2	FQ C3
Antibiotique	Sulfamethoxazole	30,1%	50,9%	36,3%
	Ofloxacin	27,4%	25,5%	19,5%
	Sulfamethazine	16,8%	1,8%	0,9%
Anticonvulsant	Carbamazepine	85,0%	66,4%	64,6%
	Acetazolamide	17,4%	20,4%	11,4%
Anti-inflammatoire	Ketoprofene	54,9%	50,0%	54,0%
	Acide niflumique	55,1%	73,2%	71,1%
Anxiolytique	Diazepam	2,8%	5,6%	3,5%
	Oxazepam	69,0%	75,5%	42,5%
	Lorazepam	10,8%	9,1%	8,9%
Hormone et steroïde	17 beta-Estradiol	0%	0,9%	0,9%
	Estrone	16,8%	0%	0%
	Diethylstilbestrol	0%	1,9%	0%
	Norethindrone	8,0%	1,8%	0%



Légende


- Sites urbains
- Sites en mauvais état écologique
- Sites de référence
- Sites industriels
- Sites agricoles

No difference between sites except for pesticides, less present in industrial sites






Onema Ineris study – surface waters





Onema Ineris study – sediments





Persistence in sediments

Antibiotics accumulate in the sediments from their market authorization date





Fig. 4. Distribution of PPs along core LOI13-2 (orange circles) and core LOI13-6 (blue diamonds) according to depth and years (age-depth model performed on core LOI13-2). Concentrations are expressed in ng g^{-1} of dried sediment. Grey markers indicate concentrations below LOQ whereas empty markers indicate concentrations below LOD. The dashed line refers to the market authorization date (found on the ANSM website, www.ansm.fr) for each compound unless otherwise specified. The evolution of WTP effluents feeding the Dhuy River is indicated on the right-hand side of the figure (Fig. 1 and Table 1).



French National campaign for the analysis of drug residues in water 2009-2010

- 45 compounds (with QLs of 1 to 50 ng/L)
- 285 raw water samples and 285 treated water samples:
- Majority of molecules not quantifiable,
- No excessive concentrations
- Raw water :
 - 2/3 groundwater, 1/3 surface water
 - 35% surface water and 70% groundwater <LQ
 - 30 molecules detected 1 time, of which 14 <LQ
 - Max Conc: 400 ng/L (1% samples)
 - Majority Cumulative Conc < 25 ng/L
 - Oxazepam, paracetamol, carbamazepine




Figure 9 : Niveaux de concentrations cumulées de résidus de médicaments dans les eaux brutes




Figure 2 : Occurrence des différentes molécules quantifiées dans les ressources en fonction de l'origine de l'eau



French National campaign for the analysis of drug residues in water 2009-2010

- Treated water :
 - 26 molecules not detected
 - 19 quantified 1 time, 5 < LQ
 - 25% with 1 to 4 molecules quantified
 - Most frequently detected molecules: epoxycarbamazepine, carbamazepine, oxazepam and hydroxybupropfen
 - > 90%, cumulative conc < 25 ng/L
 - < 5% cumulative conc < 100 ng/L; max: 131 ng/L (1 sample)
- [conc] raw water > treated water: treatment efficiency




Figure 10 : Niveaux de concentrations cumulées de résidus de médicaments dans les eaux traitées




Figure 3 : Occurrence des différentes molécules quantifiées dans les EDCH en fonction de l'origine de l'eau

